Protocol Ledger

NCT05028348 · Phase III · ACTIVE NOT RECRUITING

A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma

Interventional Phase III clinical trial protocol NCT05028348 sponsored by European Myeloma Network in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-04-19 Enrollment: 117 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05028348
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)117 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05028348
Protocol FieldVerified Registry Value
NCT IdentifierNCT05028348
Consolidated Lead SponsorEuropean Myeloma Network
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment117 participants (ACTUAL)
Registered Start Date2022-04-19
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI